Ozempic vs. Wegovy: Which Is Better for Weight Loss?

Ozempic and Wegovy contain the exact same active ingredient, semaglutide, made by the same manufacturer. The meaningful difference is dosing and regulatory approval: Wegovy is approved specifically for weight management at a higher maximum dose, while Ozempic is approved for type 2 diabetes at a lower one. In clinical trials, the higher Wegovy dose consistently produces greater weight loss, making it the stronger option when the goal is shedding pounds. But the real-world picture is more complicated than that comparison suggests, and understanding how these two products differ in practice matters more than the label on the pen.

Same Molecule, Different Prescriptions

Semaglutide belongs to a class of drugs that mimic a gut hormone called GLP-1. In the brain, it acts on regions that control appetite, dialing down hunger signals and influencing how the body regulates energy. In the rest of the body, it slows the movement of food through the stomach, enhances insulin release, and reduces glucagon, a hormone that raises blood sugar.¹ A randomized trial of oral semaglutide confirmed these appetite effects in people with obesity: participants reported less hunger, greater fullness, fewer food cravings, and better control over eating compared to placebo.²

Ozempic comes in doses of 0.5 mg, 1.0 mg, and 2.0 mg, all injected once weekly. It was developed and tested primarily in people with type 2 diabetes, where blood sugar control was the main endpoint and weight loss was a welcome secondary benefit. Wegovy uses the same injection schedule but tops out at 2.4 mg, a dose chosen specifically to maximize weight loss. It was tested in people with obesity or overweight, regardless of diabetes status. Both require a gradual dose ramp-up over several months to reduce side effects, but they climb to different ceilings.

When doctors prescribe Ozempic “off-label” for weight loss in someone without diabetes, they are using a diabetes drug at a diabetes dose for a purpose it was not formally approved for. That is legal and common, but it means the patient is getting a lower maximum dose of semaglutide than they would with Wegovy, and the clinical evidence behind it was gathered in a different population.

What the Diabetes Trials Show About Ozempic and Weight

Ozempic’s weight loss data comes primarily from the SUSTAIN trial program, which enrolled over 8,000 people with type 2 diabetes.³ Across those trials, participants on the 0.5 mg dose lost roughly 2.5 to 5.7 kg, while those on 1.0 mg lost about 2.0 to 7.9 kg, depending on which other diabetes medications they were taking. Comparator groups, meanwhile, ranged from gaining 1.5 kg to losing 3.7 kg.⁴ These results held across all body-mass-index subgroups, meaning heavier patients and lighter patients responded similarly.

In one head-to-head trial, semaglutide 1.0 mg was compared directly to liraglutide 1.2 mg (another GLP-1 drug, marketed as Victoza). Participants on semaglutide lost about 5.8 kg on average, compared to 1.9 kg with liraglutide, a difference of nearly 4 kg favoring semaglutide.⁵ The weight loss from Ozempic in diabetes trials is clinically meaningful, but it is a fraction of what the higher Wegovy dose achieves in obesity trials. That dose gap is the crux of the whole comparison.

What the Obesity Trials Show About Wegovy

Wegovy’s evidence comes from the STEP trial program, which tested semaglutide 2.4 mg in people with obesity or overweight (with at least one weight-related condition) who did not necessarily have diabetes. The results are substantially more dramatic. In the landmark STEP 1 trial, participants on semaglutide 2.4 mg lost an average of about 15% of their body weight over 68 weeks, compared to roughly 2.4% for placebo. In absolute terms, that worked out to about 15.3 kg lost versus 2.6 kg. More than half of the semaglutide group lost at least 15% of their starting weight, compared to fewer than 5% in the placebo group.⁶

A meta-analysis that pooled data from multiple STEP trials, including the two-year STEP 5 trial, found the overall effect was consistent: semaglutide 2.4 mg reduced body weight by about 12% more than placebo, with similar improvements in BMI and waist circumference.⁷ And the STEP 5 trial itself showed that people who stayed on semaglutide for two full years maintained a weight reduction of about 15%, with over three-quarters of participants achieving at least a 5% loss.⁸

To put this plainly: the Wegovy dose roughly doubles or triples the weight loss seen with Ozempic’s typical diabetes doses. Someone on Ozempic 1.0 mg for diabetes might lose 5 to 8 kg; someone on Wegovy 2.4 mg for weight management can expect to lose around 12 to 15 kg. The difference is driven primarily by dose, not by anything unique about the formulation.

Lifestyle Changes Still Matter

Both Ozempic and Wegovy are meant to be used alongside a reduced-calorie diet and increased physical activity, not instead of them. The STEP 3 trial tested semaglutide 2.4 mg combined with intensive behavioral therapy, including an initial low-calorie diet phase, and found significantly greater weight loss compared to behavioral therapy alone.⁹ The drug amplifies the effects of lifestyle changes rather than replacing them. Participants in all semaglutide trials received counseling on diet and exercise, so the results reflect what happens when the medication and behavior modification work together.

This is worth keeping in mind when comparing Ozempic and Wegovy in practice. A person who takes Wegovy but makes no changes to their eating habits will likely see less benefit than someone who pairs the medication with genuine effort. The clinical trials had both groups receiving lifestyle support, so the real-world advantage of either drug depends partly on what happens off the prescription pad.

Side Effects Are Essentially the Same

Because both drugs are semaglutide, the side effect profiles overlap almost completely. The most common complaints are gastrointestinal: nausea, vomiting, diarrhea, and constipation. These issues are most pronounced during the dose-escalation period and tend to ease as the body adjusts. Slowed movement of food through the gut is actually part of how the drug works, creating that prolonged sense of fullness, but it can tip into discomfort for some people.¹⁰

Wegovy’s higher dose can mean more intense GI symptoms during titration, though the gradual ramp-up schedule is designed to minimize this. Some people never fully tolerate the top dose and stay on a lower one, effectively narrowing the gap between the two products.

Rarer but more serious risks include pancreatitis, gallbladder disease, and a theoretical concern about thyroid tumors (based on animal studies with very high doses). One large study found that GLP-1 drug users had a higher risk of gastroparesis, a condition where the stomach empties abnormally slowly. The same study noted that when researchers properly accounted for the fact that heavier people already have elevated risks for some GI conditions, the apparent link between these drugs and acute pancreatitis weakened considerably.¹¹ In other words, some of the scary-sounding risks attributed to the drug may actually belong to the obesity it is treating.

Cardiovascular Benefits Beyond Weight

One area where Wegovy has an edge backed by a dedicated trial is cardiovascular protection. The SELECT trial, which enrolled over 17,600 adults with obesity and established cardiovascular disease but without diabetes, found that semaglutide 2.4 mg reduced the rate of major cardiovascular events (heart attack, stroke, or cardiovascular death) by 20% compared to placebo.¹² That trial was large enough and long enough to be convincing, and it led to a label expansion for Wegovy to include cardiovascular risk reduction.

Ozempic’s cardiovascular evidence comes primarily from the SUSTAIN 6 trial in people with type 2 diabetes, which also showed benefits. Together with SELECT and other trials, the accumulating evidence suggests semaglutide has cardiovascular protective effects that go beyond what you would expect from weight loss alone.¹³ For someone whose primary concern is heart health alongside weight loss, the Wegovy dose with the SELECT trial behind it is the better-supported choice.

What Happens to Muscle and Fat

A common concern with any rapid weight loss is that a substantial chunk of what you lose is lean tissue (muscle) rather than fat. Semaglutide does cause some lean mass loss, but the picture is more nuanced than the headlines suggest. In the STEP 1 exploratory analysis, semaglutide reduced total fat mass by about 19% and visceral fat by about 27%. Total lean mass dropped by roughly 10%, but because fat was lost disproportionately, the proportion of the body made up of lean tissue actually increased.¹⁴

The SEMALEAN study, which tracked body composition more closely over 12 months, found a similar pattern. Fat mass dropped by about 19% over the full year. Lean mass fell by about 3 kg in the first seven months but then stabilized, suggesting the body adapted.¹⁵ Another study confirmed both fat-free mass and skeletal muscle mass decreased significantly with semaglutide treatment, though the losses were modest in absolute terms.¹⁶

The practical takeaway is that some lean mass loss is expected and probably unavoidable when losing a large amount of weight by any method, including surgery. Resistance exercise during treatment likely helps preserve muscle, though no semaglutide trial has directly tested a structured strength-training protocol as a comparison arm. Since this concern applies equally to both Ozempic and Wegovy (same drug), the higher dose does not create a categorically different body composition outcome. It just produces more of both types of loss.

Weight Regain After Stopping

The single most important piece of information that often gets buried in discussions of these drugs: when you stop taking semaglutide, most of the lost weight comes back. The STEP 1 trial included a one-year extension period after the drug was withdrawn. Former semaglutide users regained about two-thirds of the weight they had lost. By one year after stopping, the net weight loss from baseline was only about 5.6%, down from the roughly 15% they had achieved at the end of active treatment. The cardiometabolic improvements, including blood pressure, cholesterol, and blood sugar changes, also drifted back toward where they started.¹⁷

This is not a flaw unique to semaglutide. Obesity is a chronic condition driven by biological mechanisms that persist after weight loss: metabolic rate drops, appetite-regulating hormones shift to promote regain, and the brain essentially defends the higher weight set point. The implication is that both Ozempic and Wegovy are likely lifelong treatments for most people if the goal is sustained weight management, which brings cost and access squarely into the picture.

Cost, Insurance, and Sticking With Treatment

Here is where the comparison between Ozempic and Wegovy gets messy in ways that clinical trials cannot capture. Wegovy carries a list price that is out of reach for most people without insurance coverage, and many insurers still classify weight-loss drugs as elective. Ozempic, because it is FDA-approved for diabetes, often has better insurance coverage, which is one reason so many prescriptions for it are written off-label for weight loss.

Real-world adherence data is sobering regardless of which product someone starts. A study of commercially insured adults prescribed semaglutide for weight management found that by the fifth month, nearly half had stopped treatment. Discontinuation was strongly linked to how much people had to pay out of pocket: those with the lowest copays (under $54 a month) had a 41% discontinuation rate, while those with the highest copays (over $161 a month) discontinued at a rate of 51%.¹⁷ Most users also deviated from the recommended monthly dose-escalation schedule within the first five months, meaning many never reached the target dose that clinical trials were designed around.

This creates a strange situation. On paper, Wegovy’s 2.4 mg dose is the clear winner for weight loss. In practice, a large percentage of people never reach or sustain that dose, either because of cost, side effects, or supply shortages. Someone who stays on Ozempic 1.0 mg for two years may end up with better long-term results than someone who cycles on and off Wegovy every few months because of cost or availability.

How Semaglutide Compares to Newer Drugs

The weight-loss medication landscape is evolving fast. Tirzepatide, sold as Mounjaro for diabetes and Zepbound for weight management, targets both GLP-1 and another gut hormone receptor called GIP, and it generally outperforms semaglutide on weight loss. A real-world study comparing the two found that after one year, people on semaglutide 2.4 mg lost about 14.1% of their body weight, while those on tirzepatide lost about 16.5%.¹⁸ The gap is meaningful but not enormous, and both drugs produce weight loss far beyond what was possible with older medications.

For someone comparing Ozempic and Wegovy specifically, though, the arrival of tirzepatide matters because it reframes the question. The debate is less about which semaglutide product to use and more about whether semaglutide at any dose is the right choice for your situation, given that alternatives now exist with potentially greater efficacy. Your doctor’s recommendation will factor in your medical history, insurance formulary, and whether you have diabetes in addition to excess weight.

Effects on Cravings, Alcohol, and “Food Noise”

One of the more unexpected effects reported by semaglutide users is a reduction in what many describe as “food noise,” the persistent mental chatter about what to eat next. This aligns with the drug’s action on brain regions involved in reward and appetite. Research has also flagged a potentially broader effect on addictive behaviors. A study examining medical records found that people taking semaglutide or tirzepatide showed reduced alcohol consumption compared to those on other obesity medications.¹⁹ This is still early-stage evidence, and the mechanisms are not fully worked out, but it suggests semaglutide’s effects on the brain’s reward circuitry may extend well beyond appetite for food.

These neurological effects do not differ between Ozempic and Wegovy in any studied way, though one could reasonably expect the higher dose to have a stronger impact on central pathways. For some people, this aspect of the drug experience is as important as the number on the scale. The quieting of compulsive food thoughts, the reduced interest in alcohol, the feeling that food no longer dominates their mental bandwidth: these quality-of-life changes come up repeatedly in patient accounts, even if they remain poorly quantified by formal research.

When Ozempic Might Actually Be the Practical Choice

If Wegovy produces better weight loss at its target dose, you might wonder why anyone would choose Ozempic for weight management. The reasons are almost entirely practical. Insurance coverage for Ozempic as a diabetes treatment is broader. Supply disruptions, which plagued both drugs from 2022 through 2024, sometimes affected one product more than the other. A person who has type 2 diabetes and also wants to lose weight gets both benefits from a single Ozempic prescription without needing separate diabetes and weight-loss drugs. And for someone who cannot tolerate the higher dose, the 1.0 mg or 2.0 mg Ozempic dose may be as high as their body can comfortably handle, making the Wegovy label irrelevant.

There is also the issue of clinical expectations. Losing 5 to 8 kg on Ozempic is still a clinically significant amount of weight for someone with diabetes. It can improve blood sugar control enough to reduce or eliminate other diabetes medications, lower blood pressure, and improve mobility. Not everyone needs the dramatic 15% loss that Wegovy’s trials demonstrated. For a person with diabetes, moderate and well-tolerated weight loss on Ozempic may be perfectly appropriate for their health goals, even if it falls short of what a higher dose could theoretically achieve.